PTCL Resources

Helpful resources for healthcare professionals and patients
to learn more about ISTODAX and PTCL

ISTODAX Brochure

ISTODAX Brochure

An in-depth resource that highlights the efficacy and safety information from ISTODAX clinical trials and important ISTODAX dosing information

Dosing Guide for Nurses and Pharmacists

Dosing Guide for Nurses and Pharmacists

A helpful resource, including guidelines for dose modification with ISTODAX and instructions for how to reconstitute and prepare ISTODAX for administration

My Treatment with ISTODAX Patient Guide

My Treatment with ISTODAX Patient Guide

Important information for patients about their condition and what to expect from treatment with ISTODAX

The organizations listed below can help patients access more information about their condition, as well as provide them with additional resources and support.

Listing of these resources does not constitute endorsement by Celgene Corporation of an organization or its communications.

American Cancer Society®

Non-Hodgkin Lymphoma
http://www.cancer.org/cancer/non-hodgkinlymphoma/index
(800-227-2345)

Cancer Care®

Peripheral T-Cell Lymphoma
http://www.cancercare.org/diagnosis/peripheral_t-cell_lymphoma
(800-813-HOPE) (800-813-4673)

ClinicalTrials.gov

www.clinicaltrials.gov
(online only)

Leukemia & Lymphoma Society®

Non-Hodgkin Lymphoma
http://www.lls.org/#/diseaseinformation/lymphoma/nonhodgkinlymphoma

PTCL Facts
http://www.lls.org/#/resourcecenter/freeeducationmaterials/lymphoma/peripheraltcell
(800-955-4572)

Lymphoma Research Foundation

Focus on Peripheral T-Cell Lymphoma
http://www.focusonptcl.org
(800-500-9976)

National Cancer Institute

Non-Hodgkin Lymphoma
http://www.cancer.gov/cancertopics/types/non-hodgkin
(800-4-CANCER) (800-422-6237)

Check back for updates as new resources
become available.

NEXT: PATIENT SUPPORT INFORMATION

Important Safety Information

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Peripheral T-Cell Lymphoma

The most common Grade 3/4 adverse reactions (>5%) regardless of causality in Study 3 (N=131) were thrombocytopenia (24%), neutropenia (20%), anemia (11%), asthenia/fatigue (8%), and leukopenia (6%), and in Study 4 (N=47) were neutropenia (47%), leukopenia (45%), thrombocytopenia (36%), anemia (28%), asthenia/fatigue (19%), pyrexia (17%), vomiting (9%), and nausea (6%).

Infections were the most common type of serious adverse event reported in Study 3 (N=131) and Study 4 (N=47). In Study 3, 26 patients (20%) experienced a serious infection, including 6 patients (5%) with serious treatment-related infections. In Study 4, 11 patients (23%) experienced a serious infection, including 8 patients (17%) with serious treatment-related infections.

The most common adverse reactions regardless of causality in Study 3 (N=131) were nausea (59%), asthenia/fatigue (55%), thrombocytopenia (41%), vomiting (39%), diarrhea (36%), and pyrexia (35%), and in Study 4 (N=47) were asthenia/fatigue (77%), nausea (75%), thrombocytopenia (72%), neutropenia (66%), anemia (62%), leukopenia (55%), pyrexia (47%), anorexia (45%), vomiting (40%), constipation (40%), and diarrhea (36%).

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

Please click here for Full Prescribing Information.

get flash
TO BEGIN: Select and drag a manifestation to the appropriate area on the body.
get flash
get flash